| Name | Fusion Antibodies |
|---|---|
| Epic | FAB |
| Isin | GB00BDQZGK16 |
| Industry | Medical Equipment and Services |
| Latest share price | 3.25p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £3.10 | Debt ratio | n/a |
| Shares in issue | 95.37 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -234.65 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -10 | 52-week high / low | 2.90p / 7.20p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Fusion Antibodies |
|---|---|
| Address | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Telephone | |
| Website | https://www.fusionantibodies.com/ |
| Director | Position |
|---|---|
| Dr Adrian Kinkaid | CEO |
| Dr Simon Gordon Douglas | Chairman |
| Mr Colin Walsh | Non-Executive Director |
| Mr Matthew Baker | Non-Executive Director |
| Dr Richard John Buick | Chief Scientific Officer |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/03/23 | 31/03/22 | 31/03/21 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.38 | 0.63 | 1.12 |
| Inventory / work in progress | 0.54 | 0.58 | 0.48 |
| Trade and other receivables | 0.95 | 1.65 | 1.54 |
| Cash and equivalents | 0.2 | 2.05 | 2.69 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 2.06 | 4.92 | 5.83 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.88 | 1.21 | 1 |
| Long term liabilities | 0.06 | 0.02 | 0.09 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.94 | 1.23 | 1.08 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 1.12 | 3.68 | 4.75 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 1.04 | 1.04 | 1.02 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -7.56 | -5 | -3.82 |
| Share premium account | 7.65 | 7.65 | 7.55 |
| Total equity | 1.12 | 3.68 | 4.75 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.86 | -1.32 | -1.25 |
| Pre-tax profit | -2.86 | -1.33 | -1.26 |